

Align. Measure. Perform. (AMP) Questions and Appeals Submission Form – Measurement Year 2019 AMP Commercial HMO and Medicare Advantage Quality Reports

Directions

Complete this form to submit your question or appeal about preliminary AMP MY 2019 Commercial HMO and Medicare Advantage quality reports released May 29, 2020.

1. Complete submission form below **for each health plan** you are submitting a question or appeal for.
 - a. You should include measure-specific information about your questions and appeals in the table.
 - b. All **questions** must include enough detail for AMP staff to investigate and resolve.
 - c. All **appeals** must include enough detail and documentation for AMP staff to investigate and to support the appeal. All documentation must be attached to your email submission.
 - d. **PROTECTED HEALTH INFORMATION (PHI) WILL NOT BE ACCEPTED. If you attach PHI, your email will be discarded, and you will need to restart the appeals process.**
2. Save completed form(s) and email to appeals@iha.org with the following Subject Line: [Your Organization Name] Question & Appeals Submission.

Submission Form

- 1. Organization Information** (enter the PO name, followed by the 5-digit DMHC ID and 2-digit Sub ID)

PO Name:

DMHC ID and Sub ID:

- 2. Submitter Information** (enter the name of the submitter and contact information)

Submitter Name:

Email and phone number:

- 3. Data source** (select the appropriate health plan/reporting entity for your inquiry):

- 4. Summary of Question/Appeal** (type a short summary of the data concerns. A detailed explanation of the issue should be included in the table on the following pages):

Questions & Appeals: MY 2019 AMP Commercial HMO and AMP Medicare Advantage Quality Reports

In the table below, please indicate the measure to which the question or appeal applies. Each row should reference one measure only. A complete list of eligible measures is included in the appendix of this form.

	Measure <i>List one measure per row including measure indicator as needed (e.g. age band).</i>	Product Line	Data Concern	Detailed explanation of the issue <i>Please include:</i> <ul style="list-style-type: none"> ● <i>Specific results affected (e.g. numerator, denominator, rate).</i> ● <i>A description of any data inconsistencies (e.g. does it differ from year to year, compared to other plans or to internal systems).</i> ● <i>Summary of any evidence supporting appeal (e.g. confirmation of supplemental data sent & received).</i> 	Question or Appeal?
1					
2					
3					
4					

5					
6					
7					
8					
9					
10					
11					
12					

Measure List: MY 2019 AMP Clinical Quality Domain

ACI: e-Measure (applies to all indicators):

- ACI: e-Measure: Controlling High Blood Pressure
- ACI: e-Measure: Controlling High Blood Pressure (Percent Reportable)
- ACI: e-Measure: Screening for Clinical Depression and Follow-up
- ACI: e-Measure: Screening for Clinical Depression and Follow-up (Percent Reportable)
- **Adult BMI Assessment**
- **Appropriate Testing for Pharyngitis (applies to all indicators):**
 - Appropriate Testing for Pharyngitis: Ages 18-64
 - Appropriate Testing for Pharyngitis: Ages 3-17
 - Appropriate Testing for Pharyngitis: Ages 65 and older
 - Appropriate Testing for Pharyngitis: Total Rate
- **Asthma Medication Ratio (applies to all indicators):**
 - Asthma Medication Ratio: Ages 12-18
 - Asthma Medication Ratio: Ages 19-50
 - Asthma Medication Ratio: Ages 5-11
 - Asthma Medication Ratio: Ages 51-64
 - Asthma Medication Ratio: Ages 5-64
- **Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (applies to all indicators):**
 - Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis: Ages 18-64 years
 - Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis: Ages 3 years-17 years
 - Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis: Ages 65 and older
 - Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis: Total Rate
- **Breast Cancer Screening: Ages 52-74**
- **Cervical Cancer Overscreening**
- **Cervical Cancer Screening**
- **Childhood Immunization Status (applies to all indicators):**
 - Childhood Immunization Status: DTaP
 - Childhood Immunization Status: Hepatitis A
 - Childhood Immunization Status: Hepatitis B
 - Childhood Immunization Status: Hib
 - Childhood Immunization Status: Influenza
 - Childhood Immunization Status: IPV
 - Childhood Immunization Status: MMR
 - Childhood Immunization Status: PCV
 - Childhood Immunization Status: Rotavirus
 - Childhood Immunization Status: VZV
- **Chlamydia Screening (applies to all indicators):**
 - Chlamydia Screening: Ages 16-20
 - Chlamydia Screening: Ages 21-24
 - Chlamydia Screening: All Ages (16-24)
- **Colorectal Cancer Screening: Ages 51-75**
- **Controlling High Blood Pressure (<140/90): Ages 18-85**
- **Comprehensive Diabetes Care (applies to all indicators):**
 - Comprehensive Diabetes Care: Blood Pressure Control <140/90 mm Hg
 - Comprehensive Diabetes Care: Eye Exam
 - Comprehensive Diabetes Care: HbA1c Control < 8.0%
 - Comprehensive Diabetes Care: HbA1c Poor Control > 9.0%
 - Comprehensive Diabetes Care: Medical Attention for Nephropathy

- Diabetes Care: Optimal Diabetes Care-- Combination
- **Disease Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis**
- **Immunizations for Adolescents (applies to all indicators):**
 - Immunizations for Adolescents: Combination 1 (Meningococcal and Tdap)
 - Immunizations for Adolescents: Combination 2 (Meningococcal, Tdap and HPV)
 - Immunizations for Adolescents: HPV
 - Immunizations for Adolescents: Meningococcal
 - Immunizations for Adolescents: Tdap
- **Osteoporosis Management in Women Who Had a Fracture**
- **Proportion of Days Covered by Medications (applies to all indicators):**
 - Proportion of Days Covered by Medications: Diabetes All-Class
 - Proportion of Days Covered by Medications: RAS Antagonists
 - Proportion of Days Covered by Medications: Statins
- **Statin Therapy for Patients with Cardiovascular Disease (applies to all indicators):**
 - Statin Therapy for Patients with Cardiovascular Disease: Received Statin Therapy
 - Statin Therapy for Patients with Cardiovascular Disease: Statin Adherence 80%
- **Statin Therapy for Patients with Diabetes (applies to all indicators):**
 - Statin Therapy for Patients with Diabetes: Received Statin Therapy
 - Statin Therapy for Patients with Diabetes: Statin Adherence 80%
- **Patient Experience (applies to all indicators):**
 - Patient Experience: Access Composite
 - Patient Experience: Coordination of Care Composite
 - Patient Experience: Office Staff Composite
 - Patient Experience: Overall Ratings of Care Composite (Rating of Doctor & Rating of All Healthcare)
 - Patient Experience: Provider Communication Composite
 - Patient Experience: Rating of All Healthcare
- **Encounter Rate by Service Type**
 - Encounter Rate 1: Office and Other Outpatient Services
 - Encounter Rate 2: Preventive Medicine
 - Encounter Rate 3: Ophthalmology and Optometry
 - Encounter Rate 4: Laboratory/Pathology Services
 - Encounter Rate 5: Radiology and Imaging
 - Encounter Rate 6: Ambulatory Surgery/Procedures
 - Encounter Rate 7: ED Visits
 - Encounter Rate 8: Inpatient Stays
 - Overall Professional Encounter Rate
 - Overall Facility Encounter Rate
 - Overall Rate
- **Enrollment**